202 – Randomized Trial of Long-Acting Cabotegravir and Rilpivirine in Africa (CARES): Week 96 Results
Background Evidence is required to support use of long-acting injectable therapy (LA) in Africa, where demographic factors, viral subtypes, prior treatment, archived drug resistance, and approaches to treatment delivery and monitoring differ from resource-rich settings. We previously reported non-inferior efficacy of LA versus oral antiretroviral therapy (ART) at 48 weeks, but longer-term data are needed…